MTOR and cyst: Preclinical trials based on mTOR inhibition (mTOR-I) by either the immunosuppressant sirolimus (SIR) [61,70] or everolimus (EVER) [71] demonstrated that the sirolimus injection led to increased kidney size, cyst density and tubular cell proliferation.